{"id":"https://openalex.org/W4233729482","doi":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","title":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist, Tirzepatide, on Biomarkers of Non-Alcoholic Steatohepatitis in Patients with T2DM","display_name":"Effects of Novel Dual GIP and GLP-1 Receptor Agonist, Tirzepatide, on Biomarkers of Non-Alcoholic Steatohepatitis in Patients with T2DM","publication_year":2020,"publication_date":"2020-04-14","ids":{"openalex":"https://openalex.org/W4233729482","doi":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1"},"language":"en","primary_location":{"id":"doi:10.2337/dc20-1234/suppl.12014322.v1","doi":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"volume":null,"type":"other","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","any_repository_has_fulltext":null},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5057894973","display_name":"Mark L. Hartman","orcid":"https://orcid.org/0000-0003-2396-7356","observed_orcids":["https://orcid.org/0000-0003-2396-7356"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark L. Hartman","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070639714","display_name":"Arun Jayant Sanyal","orcid":"https://orcid.org/0000-0001-8682-5748","observed_orcids":["https://orcid.org/0000-0001-8682-5748"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Arun J. Sanyal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052059601","display_name":"Rohit Seth Loomba","orcid":"https://orcid.org/0000-0002-4845-9991","observed_orcids":["https://orcid.org/0000-0002-4845-9991"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rohit Loomba","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5003206993","display_name":"Jonathan Matthew Wilson","orcid":"https://orcid.org/0000-0002-8648-600X","observed_orcids":["https://orcid.org/0000-0002-8648-600X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jonathan M. Wilson","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061113397","display_name":"Amir Nikooienejad","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amir Nikooienejad","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091446537","display_name":"Ross Bray","orcid":"https://orcid.org/0000-0002-6357-9430","observed_orcids":["https://orcid.org/0000-0002-6357-9430"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ross Bray","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030157221","display_name":"Chrisanthi A. Karanikas","orcid":"https://orcid.org/0009-0008-0614-8264","observed_orcids":["https://orcid.org/0009-0008-0614-8264"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Chrisanthi Karanikas","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072130761","display_name":"Kevin L. Duffin","orcid":"https://orcid.org/0000-0002-1656-8982","observed_orcids":["https://orcid.org/0000-0002-1656-8982"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Kevin L. Duffin","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081732583","display_name":"Deborah A. Robins","orcid":"https://orcid.org/0000-0001-9694-7319","observed_orcids":["https://orcid.org/0000-0001-9694-7319"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Deborah A. Robins","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5040811419","display_name":"Axel Haupt","orcid":"https://orcid.org/0000-0003-4502-0470","observed_orcids":["https://orcid.org/0000-0003-4502-0470"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Axel Haupt","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10351","display_name":"Liver Disease Diagnosis and Treatment","score":0.9785000085830688,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.016200000420212746,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tirzepatide","display_name":"tirzepatide","score":1.0},{"id":"https://openalex.org/keywords/gip-glp-1-receptor-agonist","display_name":"GIP/GLP-1 receptor agonist","score":0.7350000143051147},{"id":"https://openalex.org/keywords/non-alcoholic-steatohepatitis","display_name":"nonalcoholic steatohepatitis","score":0.8980000019073486},{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.9210000038146973},{"id":"https://openalex.org/keywords/liver-fibrosis-markers","display_name":"liver fibrosis markers","score":0.8370000123977661},{"id":"https://openalex.org/keywords/cytokeratin-18","display_name":"cytokeratin 18","score":0.8799999952316284},{"id":"https://openalex.org/keywords/procollagen-type-iii","display_name":"type III procollagen","score":0.8500000238418579},{"id":"https://openalex.org/keywords/alanine-aminotransferase","display_name":"alanine aminotransferase","score":0.9290000200271606},{"id":"https://openalex.org/keywords/adiponectin","display_name":"adiponectin","score":0.9049999713897705},{"id":"https://openalex.org/keywords/dulaglutide","display_name":"dulaglutide","score":0.9789999723434448},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.5989999771118164}],"concepts":[{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.8123704195022583},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.6659059524536133},{"id":"https://openalex.org/C2779478299","wikidata":"https://www.wikidata.org/wiki/Q2335423","display_name":"Steatohepatitis","level":4,"score":0.5993715524673462},{"id":"https://openalex.org/C2776782570","wikidata":"https://www.wikidata.org/wiki/Q357439","display_name":"Adiponectin","level":4,"score":0.5824121832847595},{"id":"https://openalex.org/C2779829264","wikidata":"https://www.wikidata.org/wiki/Q21011228","display_name":"Dulaglutide","level":5,"score":0.5810544490814209},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5518935322761536},{"id":"https://openalex.org/C185280430","wikidata":"https://www.wikidata.org/wiki/Q14909910","display_name":"Glucagon-like peptide 1 receptor","level":4,"score":0.523841381072998},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.5126990079879761},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4446636736392975},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.3513551950454712},{"id":"https://openalex.org/C2780533449","wikidata":"https://www.wikidata.org/wiki/Q417762","display_name":"Exenatide","level":4,"score":0.33258047699928284},{"id":"https://openalex.org/C2778772119","wikidata":"https://www.wikidata.org/wiki/Q6058862","display_name":"Fatty liver","level":3,"score":0.32227182388305664},{"id":"https://openalex.org/C2777391703","wikidata":"https://www.wikidata.org/wiki/Q1053470","display_name":"Insulin resistance","level":3,"score":0.275360107421875},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.19475963711738586},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.1677931845188141},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.12984278798103333},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.2337/dc20-1234/suppl.12014322.v1","doi":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"}],"best_oa_location":{"id":"doi:10.2337/dc20-1234/suppl.12014322.v1","doi":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","is_oa":true,"landing_page_url":"https://doi.org/10.2337/dc20-1234/suppl.12014322.v1","pdf_url":null,"source":null,"license":"cc-by-nc-sa","license_id":"https://openalex.org/licenses/cc-by-nc-sa","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":null,"raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W3015345942","https://openalex.org/W2948256006","https://openalex.org/W4233836373","https://openalex.org/W4313813923","https://openalex.org/W6930617537","https://openalex.org/W7140236647","https://openalex.org/W4413054350","https://openalex.org/W4410799153","https://openalex.org/W4412044923","https://openalex.org/W7167468601"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"determine":[2],"the":[3],"effect":[4],"of":[5,10,22],"tirzepatide,":[6],"a":[7,76],"dual":[8],"agonist":[9],"glucose-dependent":[11],"insulinotropic":[12],"polypeptide":[13],"(GIP)":[14],"and":[15,26,33,71,103,125,129,148,162],"glucagon-like":[16],"peptide-1":[17],"(GLP-1)":[18],"receptors,":[19],"on":[20],"biomarkers":[21,161],"nonalcoholic":[23],"steatohepatitis":[24],"(NASH)":[25],"fibrosis":[27],"in":[28,59,75,86,165],"T2DM":[29,35,166],"patients.":[30,167],"Research":[31],"Design":[32],"Methods:":[34],"patients":[36],"received":[37],"either":[38],"once":[39],"weekly":[40],"tirzepatide":[41,94,115,143,156],"(1,":[42],"5,":[43,99],"10,":[44,100],"or":[45,51],"15":[46,101,106,135,149],"mg),":[47,50,96,128],"dulaglutide":[48,131],"(1.5":[49],"placebo":[52,120,146],"for":[53,121,132],"26":[54,111],"weeks.":[55,112],"Changes":[56],"from":[57,84,140],"baseline":[58,85,141],"alanine":[60],"aminotransferase":[61,64],"(ALT),":[62],"aspartate":[63],"(AST),":[65],"Keratin-18":[66],"(K-18),":[67],"Procollagen":[68],"III":[69],"(Pro-C3),":[70],"adiponectin,":[72],"were":[73,108,116],"analyzed":[74],"modified":[77],"intent-to-treat":[78],"population.":[79],"Results:":[80],"Significant":[81],"(p<0.05)":[82],"reductions":[83],"ALT":[87,133],"(all":[88,91],"groups),":[89],"AST":[90],"groups,":[92],"except":[93],"10":[95],"K-18":[97,122],"(tirzepatide":[98,105],"mg)":[102,107,124],"Pro-C3":[104,126],"observed":[109],"at":[110],"Decreases":[113],"with":[114,119,130,142,145],"significant":[117],"compared":[118,144],"(10":[123,147],"(15":[127],"(10,":[134],"mg).":[136,150],"Adiponectin":[137],"significantly":[138,158],"increased":[139,163],"Conclusions:":[151],"In":[152],"post-hoc":[153],"analyses,":[154],"higher":[155],"doses":[157],"decreased":[159],"NASH-related":[160],"adiponectin":[164]},"counts_by_year":[],"updated_date":"2026-10-14T16:39:01.820549","created_date":"2022-05-12T00:00:00"}